Page last updated: 2024-09-03

sr 27897 and cyclic gmp

sr 27897 has been researched along with cyclic gmp in 1 studies

Compound Research Comparison

Studies
(sr 27897)
Trials
(sr 27897)
Recent Studies (post-2010)
(sr 27897)
Studies
(cyclic gmp)
Trials
(cyclic gmp)
Recent Studies (post-2010) (cyclic gmp)
4831622,3463334,062

Protein Interaction Comparison

ProteinTaxonomysr 27897 (IC50)cyclic gmp (IC50)
Phosphodiesterase Bos taurus (cattle)0.1
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)2.4
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)2.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnone, M; Gonalons, N; Gueudet, C; Gully, D; Heaulme, M; Keane, P; Le Fur, G; Poncelet, M; Santucci, V; Thurneyssen, O1

Other Studies

1 other study(ies) available for sr 27897 and cyclic gmp

ArticleYear
Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
    Naunyn-Schmiedeberg's archives of pharmacology, 1993, Volume: 348, Issue:1

    Topics: Animals; Apomorphine; Brain; Cyclic GMP; Dose-Response Relationship, Drug; Female; Indoleacetic Acids; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cholecystokinin; Thiazoles

1993